NASDAQ$PRCT

PROCEPT BioRobotics Corporation · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

PROCEPT BioRobotics experienced significant revenue growth driven by US sales and expanded its install base.

PROCEPT BioRobotics reported a strong first quarter in 2022, with total revenue increasing by 97% compared to the prior year period. The growth was primarily driven by U.S. revenues, including system sales and handpiece revenue. The company also increased its full year 2022 total revenue guidance range to $58.0 million to $62.0 million.

  • Total revenue for Q1 2022 was $14.2 million, a 97% increase compared to Q1 2021.
  • U.S. system and rental revenue reached $7.8 million, a 70% increase year-over-year.
  • U.S. handpiece and consumables revenue was $4.4 million, a 174% increase year-over-year.
  • Fiscal year 2022 total revenue guidance was increased to a range of $58.0 million to $62.0 million.

Headline financials

Total Revenue

$14.2M

Previous: $7.19M+97.4%
EPS (adj)

-$0.39

Previous: -$12.59+96.9%
Gross Margin

54.0%

Previous: 49.0%+10.2%
Capital Expenditures

-$55K

Previous: $39K-241.0%
Free Cash Flow

-$17.2M

Previous: -$15.2M-13.1%
Net Income

-$17.2M

Previous: -$12.8M-34.0%
Operating Income

-$15.7M

Previous: -$11.3M-38.4%
Gross Profit

$7.69M

Previous: $3.53M+118.1%
Cash & Equivalents

$284M

Previous: $86.1M+230.1%
Total Assets

$321M

No prior period
Stock-Based Comp

$1.55M

Previous: $650K+138.8%

Revenue & EPS history

PROCEPT BioRobotics · Revenue · Quarterly

$14.2M

Q1 2022+97.4%vs Q1 2021
Beat estimate in 6 of 10 quarters(60%)
ActualEstimate

Revenue by segment

PROCEPT BioRobotics · $13.7M total across 4 segments · Q1 2022

  • U.S. System Sales
    $7.75M+70.1%
  • U.S. Consumables
    $4.44M+174.0%
  • Intl. Consumables
    $745K+23.5%
  • Intl. System Sales
    $742K+172.8%

Forward guidance

The Company projects revenue for the full year 2022 to range from $58 million to $62 million, which represents 68% to 80% growth over the company’s prior year revenue. The Company reiterates full year 2022 Adjusted EBITDA loss to be in the range of ($63) million to ($60) million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+1.3%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+0.6%

Avg return

30 days after

45%

10 / 22 earnings

Positive

+40.6%

Q3 2024

Best reaction

-15.2%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+10.7%+16.0%+21.3%
Q4 2025-15.2%-5.7%-5.3%
Q3 2025+1.6%-7.5%+2.7%
Q1 2025-5.6%+1.1%+3.0%
Q4 2024+8.6%-3.4%-4.2%
Q3 2024+40.6%+34.2%+41.5%
Q2 2024-9.4%-4.3%+24.8%
Q1 2024+16.5%+15.9%+25.3%
Q4 2023+1.1%+0.5%+1.2%
Q3 2023+21.7%+22.5%+39.5%
Q2 2023-6.7%-10.3%-18.4%
Q1 2023-15.0%-20.1%-10.9%
Q4 2022+1.2%-4.3%-28.7%
Q3 2022-9.9%-8.4%+5.8%
Q2 2022+4.3%+4.3%+0.2%
Q1 2022-5.1%-17.9%+19.5%
Q4 2021+1.2%+5.9%+38.7%
Q3 2020-2.2%-4.5%-28.0%
Q4 2020-2.2%-4.5%-28.0%
Q2 2021-2.2%-4.5%-28.0%
Q1 2021-2.2%-4.5%-28.0%
Q3 2021-4.4%-3.9%-29.6%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro